Ganetespib was more effective than single-agent vemurafenib in melanoma cell lines driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF), because this protein is a very sensitive HSP90 client. This evidence concerns the gene BRAF and melanoma.